Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics adds Will Sargent to team

Join as VP of commercial strategy and investor relations
Will Sargent Nabriva Therapeutics

Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.

Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.

He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need.

“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”

Dr Colin Broom, CEO of Nabriva, added: “Will's strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”

14th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics